EUVIMEDDescobrir EUVIMED
Open access · CC BY 4.0

Probing 3‐Amino‐2 H ‐Azaindazoles as Allosteric Inhibitors of the Protein Tyrosine Phosphatase SHP2

Machoud Amoussa, Nina-Louisa Efrém, Feng Li, Ziqiong Guo, Yvette Roske, Katrin Jana Frank, Szymon Pach, Clemens Alexander Wolf, Feng Bo, Marina Lesina, Mika Kintzel, Rana Alsalim and 9 more

ChemMedChem · 2026-06-15 · 21 (11)

DOI: 10.1002/cmdc.70341 ↗

At a glance

Journal article in ChemMedChem, published online on 2026-06-14. Written by Machoud Amoussa and 20 co-authors. Institution: Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Berlin, Germany. Major MEDLINE topics: Protein Tyrosine Phosphatase, Non-Receptor Type 11, Indazoles, Enzyme Inhibitors. 63 references. The full text is freely available (open access, CC BY 4.0). Funded by: Deutsche Forschungsgemeinschaft, European Union's Horizon 2020 research and innovation program.

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

Src homology 2‐containing protein tyrosine phosphatase 2 (SHP2) is an attractive therapeutic target in oncology and immunology‐related disorders. However, developing novel phosphatase inhibitors that combine high potency, selectivity, cellular permeability, and drug‐like properties remains challenging. The discovery of an allosteric mode of inhibition for SHP2 was a breakthrough, enabling the development of selective inhibitors that stabilize the phosphatase in its inactive conformation. We identified 2 H ‐indazoles as a privileged and underexplored scaffold. Using our recently described palladium‐catalyzed domino reaction as a key synthetic step, 3‐amino‐2 H ‐indazoles were efficiently accessed from readily available precursors, enabling rapid exploration of novel allosteric inhibitors of SHP2. This approach led to compound 17g , a potent and selective allosteric SHP2 inhibitor (SHP2 WT IC 50 = 49 nM). High‐resolution structural characterization by X‐ray crystallography revealed binding within the SHP2 allosteric tunnel. Consistent with its biological activity, compound 17g also effectively suppressed ERK phosphorylation in MV‐4‐11, Panc‐1, and KYSE520 cells with an IC 50 of 50, 250, and 410 nM, respectively. These findings not only highlight the therapeutic potential of 2 H ‐azaindazoles as a new class of SHP2 inhibitors but also underscore the importance of advances in efficient synthetic methodologies for constructing novel heterocyclic scaffolds and substitution patterns.

Subjects

MeSH terms (MEDLINE)

Protein Tyrosine Phosphatase, Non-Receptor Type 11IndazolesEnzyme InhibitorsHumansAllosteric RegulationStructure-Activity RelationshipCrystallography, X-RayMolecular StructureCell Line, TumorDose-Response Relationship, DrugModels, Molecular

Author keywords

2H‐indazolesSHP2allosteric inhibitionheterocyclesphosphatases

Substances

Protein Tyrosine Phosphatase, Non-Receptor Type 11IndazolesEnzyme InhibitorsPTPN11 protein, human

Authors and institutions

  • Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Berlin, Germany.
  • Freie Universität, Molecular Design Group, Institute of Pharmacy, Berlin, Germany.
  • Karlsruhe Institute of Technology, Organic Chemistry I, Institute of Organic Chemistry, Karlsruhe, Germany.
  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.
  • State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Pudong, Shanghai, China.
  • Max Delbrück Center for Molecular Medicine (MDC), Structural Biology, Campus Berlin-Buch, Berlin, Germany.

ORCID profiles: György M Keserű, Gerhard Wolber, Jia Li, Marc Nazaré

Funding

  • Deutsche Forschungsgemeinschaft
  • European Union's Horizon 2020 research and innovation program

Cite

APA

Amoussa, M., Efrém, N. L., Li, F., Guo, Z., Roske, Y., Frank, K. J., Pach, S., Wolf, C. A., Bo, F., Lesina, M., Kintzel, M., Alsalim, R., Zeitz, V., Csorba, N., Radetzki, S., Keserű, G. M., Daumke, O., Algül, H., Wolber, G., …, & Nazaré, M. (2026). Probing 3‐Amino‐2 H ‐Azaindazoles as Allosteric Inhibitors of the Protein Tyrosine Phosphatase SHP2. ChemMedChem, 21(11). https://doi.org/10.1002/cmdc.70341

Vancouver

Amoussa M, Efrém NL, Li F, Guo Z, Roske Y, Frank KJ, et al. Probing 3‐Amino‐2 H ‐Azaindazoles as Allosteric Inhibitors of the Protein Tyrosine Phosphatase SHP2. ChemMedChem. 2026;21(11). doi:10.1002/cmdc.70341

BibTeX
@article{Amoussa2026,
  author = {Amoussa, Machoud and Efrém, Nina-Louisa and Li, Feng and Guo, Ziqiong and Roske, Yvette and Frank, Katrin Jana and Pach, Szymon and Wolf, Clemens Alexander and Bo, Feng and Lesina, Marina and Kintzel, Mika and Alsalim, Rana and Zeitz, Victoria and Csorba, Noémi and Radetzki, Silke and Keserű, György M and Daumke, Oliver and Algül, Hana and Wolber, Gerhard and Li, Jia and Nazaré, Marc},
  title = {Probing 3‐Amino‐2 H ‐Azaindazoles as Allosteric Inhibitors of the Protein Tyrosine Phosphatase SHP2},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {11},
  doi = {10.1002/cmdc.70341}
}
Start for free →